Epoprostenol in pulmonary arterial hypertension

Jacobs, Wouter; Vonk‐Noordegraaf, Anton

doi:10.1517/17425250802622962

Cited by 8 publications

(6 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhalation of PGI 2 reduces pulmonary artery pressure and pulmonary vascular resistance in patients with residual pulmonary hypertension [ 122 ]. Epoprostenol, synthetic PGI 2 sodium under the name of Flolan ® or in the new formulation of Veletri ® was the first available drug for treating PAH [ 123 ]. The PGI 2 analogs developed afterward include beraprost, iloprost, treprostinil, and selexipag administered by oral, intravenous, subcutaneous, or inhalation route, improving survival in patients with PAH [ 124 ].…”

Section: Regulation Of Blood Pressurementioning

confidence: 99%

Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease

Zhou¹,

Khan

Xiao

et al. 2021

IJMS

103

View full text Add to dashboard Cite

Arachidonic acid (AA) is an essential fatty acid that is released by phospholipids in cell membranes and metabolized by cyclooxygenase (COX), cytochrome P450 (CYP) enzymes, and lipid oxygenase (LOX) pathways to regulate complex cardiovascular function under physiological and pathological conditions. Various AA metabolites include prostaglandins, prostacyclin, thromboxanes, hydroxyeicosatetraenoic acids, leukotrienes, lipoxins, and epoxyeicosatrienoic acids. The AA metabolites play important and differential roles in the modulation of vascular tone, and cardiovascular complications including atherosclerosis, hypertension, and myocardial infarction upon actions to different receptors and vascular beds. This article reviews the roles of AA metabolism in cardiovascular health and disease as well as their potential therapeutic implication.

show abstract

Section: Regulation Of Blood Pressurementioning

confidence: 99%

Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease

Zhou¹,

Khan

Xiao

et al. 2021

IJMS

103

View full text Add to dashboard Cite

show abstract

“…Epoprostenol and prostaglandin I2 (PGI2) derivatives: Epoprostenol as a synthetic derivative of PGI2 received FDA approval in 1995. PGI2 acts as a direct vasodilator and also a cytoprotective agent which inhibits platelet aggregation [ 108 - 110 ]. Epoprostenol has beneficial effects on PAH symptoms, disease progression, 6-MWD and survival [ 111 - 115 ].…”

Section: Managementmentioning

confidence: 99%

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities

2021

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs). While imatinib is known as the first-line treatment of CML, in some cases other TKIs including dasatinib, nilotinib, bosutinib, and ponatinib may be preferred. Dasatinib, a second-generation TKI, inhibits multiple family kinases including BCR-ABL, SRC family kinases, receptor kinases, and TEC family kinases. It is effective against most imatinib-resistant cases except T315I mutation. Despite the superiority of dasatinib in its hematologic and cytogenetic responses in CML compared to imatinib, its potentially harmful pulmonary complications including pleural effusion (PE) and pulmonary arterial hypertension (PAH) may limit its use. Appropriate management of these serious adverse reactions is critical in both improving the quality of life and the outcome of the patient. In this narrative review, we will scrutinize the pulmonary complications of dasatinib and focus on the management of these toxicities.

show abstract

“…The first of these was the prostacyclin analogue epoprostenol, which was approved in 1995 in the USA before being licensed, a year later, in Europe. This treatment is still regarded as the gold standard to which other therapies should be compared [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience

Sitbon

Vonk‐Noordegraaf

2017

Eur Respir Rev

View full text Add to dashboard Cite

Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20 years since the introduction of this prostacyclin analogue, the outlook for patients with PAH has improved, with survival rates now double those from the era before the development of disease-specific treatments. Today, there are a large amount of data on the clinical role of prostacyclin treatments and a body of evidence attesting the efficacy of epoprostenol in improving exercise capacity, key haemodynamic parameters and PAH symptoms, as well as in reducing mortality. The place of epoprostenol in the therapeutic management of PAH continues to evolve, with the development of new formulations and use in combination with other drug classes. In this review, we provide a historical perspective on the first 20 years of epoprostenol, a therapy that led to evidence-based study of PAH-specific treatments and the subsequent expansion of treatment options for PAH.

show abstract

Epoprostenol in pulmonary arterial hypertension

Cited by 8 publications

References 89 publications

Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease

Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience

Contact Info

Product

Resources

About